Denali Therapeutics Inc. (DNLI)

Market Cap	3.51B
Revenue (ttm)	n/a
Net Income (ttm)	-427.49M
Shares Out	143.92M
EPS (ttm)	-2.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	767,094
Open	24.18
Previous Close	24.34
Day's Range	23.82 - 24.83
52-Week Range	14.56 - 33.33
Beta	1.39
Analysts	Strong Buy
Price Target	38.90 (+59.3%)
Earnings Date	Nov 6, 2024

About DNLI

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HE...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 8, 2017
• Employees: 445
• Stock Exchange: NASDAQ
• Ticker Symbol: DNLI
• Website: https://www.denalitherapeutics.com

Financial Performance

In 2023, Denali Therapeutics's revenue was $330.53 million, an increase of 204.74% compared to the previous year's $108.46 million. Losses were -$145.22 million, -55.45% less than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for DNLI stock is "Strong Buy." The 12-month stock price forecast is $38.9, which is an increase of 59.30% from the latest price.

Price Target

$38.9

(59.30% upside)

Analyst Consensus: Strong Buy